ALSO NOTED: GSK preps for India drug launches; Watson proceeds with challenge to Bayer drug;

> GlaxoSmithKline is preparing to launch its breast cancer drug Tykerb in India by early next year, with critical care and cardio drugs to follow. Report

> The 30-month clock is now ticking on Watson Pharmaceuticals' FDA application for its version of Bayer's Yaz contraceptive; the generics maker filed for approval two days after Bayer sued to stop the copycat drug. Release

> Japanese drug makers Daiichi Sankyo and Astellas Pharma, who are vying for the No. 2 ranking in their country, posted solid sales for the first half of the year. Report

> China blacklisted 16 misleading drug ads, bringing the total number of unacceptable ads aired since March to 26,644; some 11 drug makers have had their advertising licenses revoked for false advertising. Report

> A top Army trauma surgeon has drawn fire for using a NovoNordisk hemophilia drug off-label to stanch bleeding from war wounds, but he has plenty of fans who believe he's revolutionizing soldiers' care. Report

> Pfizer researchers rolled out the data on torcetrapib--the would-be blockbuster felled by data indicating a heightened risk of death and stroke--at the annual scientific meeting of the American Heart Association. And the numbers were being carefully scrutinized by Merck and Roche, which are advancing a group of similar drugs. Report

> Momenta Pharmaceuticals took its turn at the Wall Street whipping post as investors respond to the news that the FDA has rejected its generic version of the anti-clotting drug Lovenox, which is made by Sanofi. Report

> Novartis is staring at some serious problems rolling out its diabetes drug Galvus. Report

> Neural stem cells were used to stimulate the learning and memory abilities of mice engineered to mimic the severe disabilities produced by Alzheimer's and stroke. Report

> A chemistry professor at the University of Illinois at Urbana-Champagne says that an iron-based catalyst she developed with a colleague could speed the drug development and manufacturing. Report

And Finally... A genetic modification of a single metabolism gene helped scientists create a new breed of supermouse that can run faster and longer than ever possible. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.